Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-14-061643
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-10-03 16:09:13
Reporting Period:
2014-10-01
Filing Date:
2014-10-03
Accepted Time:
2014-10-03 16:09:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1488613 Foundation Medicine Inc. FMI Services-Medical Laboratories (8071) 271316416
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1457809 Kevin Krenitsky 150 Second Street
C/o Foundation Medicine, Inc.
Cambridge MA 02141
Chief Commercial Officer & Svp No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-09-30 203 $0.00 140,681 No 5 J Direct
Common Stock Disposition 2014-10-01 70 $18.75 140,611 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 J Direct
No 4 S Direct
Footnotes
  1. Acquired pursuant to vesting and release of shares on September 30, 2014 pursuant to a Restricted Stock Unit award granted on April 9, 2014.
  2. The reporting person previously reported all restricted stock units granted to the reporting person on April 9, 2014 in Table I of the Form 4/A filed on May 27, 2014. As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect this vesting event.
  3. Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person.
  4. The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.70 to $18.83, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.